In Vivo Development of High-Level Fluoroquinolone Resistance in Streptococcus pneumoniae in Chronic Obstructive Pulmonary Disease

Citations Over TimeTop 12% of 2005 papers

Abstract

Patients with chronic obstructive pulmonary disease are generally subjected to multiple regimens of antimicrobial treatment. The development of high-level levofloxacin resistance (i.e., a minimum inhibitory concentration >8 mu g/mL) in 8 patients whose previous pneumococcal isolates showed susceptibility is described. Molecular methods were used to characterize the strains and to study the sequential changes in fluoroquinolone targets.

Related Papers

• → Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States(2005)54 cited
• → High prevalence of multiresistance in levofloxacin-nonsusceptible Streptococcus pneumoniae isolates in Korea(2013)16 cited
• → Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model(2005)9 cited
• → Pharmacodynamics of Moxifloxacin and Levofloxacin at Simulated Epithelial Lining Fluid Drug Concentrations against Streptococcus pneumoniae(2004)42 cited
• → Characterization and Dynamics of Middle Ear Fluid and Nasopharyngeal Isolates of Streptococcus pneumoniae from 12 Children Treated with Levofloxacin(2007)5 cited